Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00801268 |
Recruitment Status :
Terminated
(high rate of drop-out)
First Posted : December 3, 2008
Last Update Posted : March 30, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Polycystic Kidney | Drug: tripterygium wilfordii Drug: Emodin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: emodin |
Drug: Emodin
100mg/d
Other Name: Frangula emodin,Frangulic acid |
Experimental: Triptolide Woldifii
TW60mg/d
|
Drug: tripterygium wilfordii
TW,60mg/d |
- MRI calculated kidney volume, eGFR [ Time Frame: Every 3-6months ]
- End-stage kidney disease (ESRD) [ Time Frame: every 2months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically established ADPKD
- eGFR>30ml/min.
- Chinese nationality
Exclusion Criteria:
- Uncontrolled infections
- Non-ADPKD complications

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801268
China, Jiangsu | |
Liu ZH, Yao XD,Chen X,Hu YL | |
Nanjing, Jiangsu, China, 210002 | |
Yao Xiaodan | |
Nanjing, Jiangsu, China, 210002 |
Principal Investigator: | Liu Zhihong, Master | Research Institute of Nephrology, Jinling Hospital |
Responsible Party: | Zhi-Hong Liu, M.D., professor, Nanjing University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00801268 |
Other Study ID Numbers: |
NJCT-0802 |
First Posted: | December 3, 2008 Key Record Dates |
Last Update Posted: | March 30, 2015 |
Last Verified: | March 2015 |
polycystic kidney disease tripterygium wilfordii |
Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Dominant Urologic Diseases Kidney Diseases, Cystic Abnormalities, Multiple Congenital Abnormalities Ciliopathies |
Genetic Diseases, Inborn Emodin Cathartics Gastrointestinal Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |